Heart failure following transcatheter aortic valve replacement

References

• Dweck Marc R, Boon Nicholas A, Newby david E. Calcific aortic stenosis. J Am Coll Cardiol. 2012;60(19):1854–1863.
   PubMed Web of Science ®Google Scholar
• Braunwald E. Aortic Stenosis: Then and Now. Circulation. 2018;137(20):2099–2100.
   PubMed Web of Science ®Google Scholar
• Gotzmann M, Rahlmann P, Hehnen T, et al. Heart failure in severe aortic valve stenosis: prognostic impact of left ventricular ejection fraction and mean gradient on outcome after transcatheter aortic valve implantation. Eur J Heart Fail. 2012;14(10):1155–1162.
   PubMed Web of Science ®Google Scholar
• Baumgartner H, Falk V, Bax JJ, et al. ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017;38(36):2739–2791.
   PubMed Web of Science ®Google Scholar
• Puri R, Chamandi C, Rodriguez-Gabella T, et al. Future of transcatheter aortic valve implantation — evolving clinical indications. Nat Rev Cardiol. 2018;15(1):57–65.
   PubMed Web of Science ®Google Scholar
• Grover FL, Vemulapalli S, Carroll JD, et al. 2016 Annual Report of The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. J Am Coll Cardiol. 2017;69(10):1215–1230.
   PubMed Web of Science ®Google Scholar
• Carroll JD, Mack MJ, Vemulapalli S, et al. STS-ACC TVT Registry of Transcatheter Aortic Valve Replacement. J Am Coll Cardiol. 2020;76(21):2492–2516.
   PubMed Web of Science ®Google Scholar
• Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380(18):1695–1705.
   PubMed Web of Science ®Google Scholar
• *Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med. 2019;380(18):1706–1715.
   PubMed Web of Science ®Google Scholar
• Babaliaros V, Devireddy C, Lerakis S, et al. Comparison of transfemoral transcatheter aortic valve replacement performed in the catheterization laboratory (minimalist approach) versus hybrid operating room (standard approach): outcomes and cost analysis. JACC Cardiovasc Interv. 2014;7(8):898–904.
   PubMed Web of Science ®Google Scholar
• *Rodés-Cabau J, Ellenbogen KA, Krahn AD, et al. Management of conduction disturbances associated with transcatheter aortic valve replacement: JACC scientific expert panel. J Am Coll Cardiol. 2019;74(8):1086–1106.
   PubMed Web of Science ®Google Scholar
• Nazzari H, Nm H, Ezekowitz J, et al. The relationship between heart-failure hospitalization and mortality in patients receiving transcatheter aortic valve replacement. Can J Cardiol. 2019;35(4):413–421.
   PubMed Web of Science ®Google Scholar
• *Nombela-Franco L, del Trigo M, Morrison-Polo G, et al. Incidence, Causes, and Predictors of Early (≤30 Days) and Late Unplanned Hospital Readmissions After Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv. 2015;8(13):1748–1757.
   PubMed Web of Science ®Google Scholar
• *Holmes DR, Brennan JM, Rumsfeld JS, et al. Clinical outcomes at 1 year following transcatheter aortic valve replacement. JAMA. 2015;313(10):1019–1028.
   PubMed Web of Science ®Google Scholar
• Franzone A, Pilgrim T, Arnold N, et al. Rates and predictors of hospital readmission after transcatheter aortic valve implantation. Eur Heart J. 2017;38(28):2211–2217.
   PubMed Web of Science ®Google Scholar
• Forcillo J, Condado JF, Binongo JN, et al. Readmission rates after transcatheter aortic valve replacement in high- and extreme-risk patients with severe aortic stenosis. J Thorac Cardiovasc Surg. 2017;154(2):445–452.
   PubMed Web of Science ®Google Scholar
• Kolte D, Khera S, Sardar MR, et al. Thirty-day readmissions after transcatheter aortic valve replacement in the united states: insights from the nationwide readmissions database. Circ Cardiovasc Interv. 2017;10(1).
   Web of Science ®Google Scholar
• Barbanti M, Petronio AS, Ettori F, et al. 5-Year outcomes after transcatheter aortic valve implantation with corevalve prosthesis. JACC Cardiovasc Interv. 2015;8(8):1084–1091.
   PubMed Web of Science ®Google Scholar
• Galat A, Guellich A, Bodez D, et al. Aortic stenosis and transthyretin cardiac amyloidosis: the chicken or the egg? Eur Heart J. 2016;37(47):3525–3531.
   PubMed Web of Science ®Google Scholar
• **Khan F, Okuno T, Malebranche D, et al. Transcatheter aortic valve replacement in patients with multivalvular heart disease. JACC Cardiovasc Interv. 2020;13(13):1503–1514.
   PubMed Web of Science ®Google Scholar
• Pibarot P, Hahn RT, Weissman NJ, et al. Association of Paravalvular Regurgitation With 1-Year Outcomes After Transcatheter Aortic Valve Replacement With the SAPIEN 3 Valve. JAMA Cardiol. 2017;2(11):1208–1216.
   PubMed Web of Science ®Google Scholar
• **Faroux L, Chen S, Muntané-Carol G, et al. Clinical impact of conduction disturbances in transcatheter aortic valve replacement recipients: a systematic review and meta-analysis. Eur Heart J. 2020;41(29):2771–2781.
   PubMed Web of Science ®Google Scholar
• *Durand E, Doutriaux M, Bettinger N, et al. Incidence, prognostic impact, and predictive factors of readmission for heart failure after transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2017;10(23):2426–2436.
   PubMed Web of Science ®Google Scholar
• Harbaoui B, Durand E, Dupré M, et al. Significance of the CAPRI risk score to predict heart failure hospitalization post-TAVI: the CAPRI-HF study. Int J Cardiol. 2019;296:98–102.
   PubMed Web of Science ®Google Scholar
• Guedeney P, Huchet F, Manigold T, et al. Incidence of, risk factors for and impact of readmission for heart failure after successful transcatheter aortic valve implantation. Arch Cardiovasc Dis. 2019;112(12):765–772.
   PubMed Web of Science ®Google Scholar
• **Auffret V, Bakhti A, Leurent G, et al. Determinants and impact of heart failure readmission following transcatheter aortic valve replacement. Circ Cardiovasc Interv. 2020;13(7):e008959.
   PubMed Web of Science ®Google Scholar
• Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J. 2007;154(2):260–266.
   PubMed Web of Science ®Google Scholar
• Urena M, Webb JG, Eltchaninoff H, et al. Late cardiac death in patients undergoing transcatheter aortic valve replacement: incidence and predictors of advanced heart failure and sudden cardiac death. J Am Coll Cardiol. 2015;65(5):437–448.
   PubMed Web of Science ®Google Scholar
• Philippe P, Dumesnil Jean G, Low-Flow P. Low-Gradient Aortic Stenosis. Circulation. 2013;128(16):1729–1732.
   PubMed Web of Science ®Google Scholar
• Luo X, Zhao Z, Chai H, et al. Efficacy of transcatheter aortic valve implantation in patients with aortic stenosis and reduced LVEF. A systematic review. Herz. 2015;40(Suppl 2):168–180.
   Google Scholar
• Eleid MF, Goel K, Murad MH, et al. Meta-analysis of the prognostic impact of stroke volume, gradient, and ejection fraction after transcatheter aortic valve implantation. Am J Cardiol. 2015;116(6):989–994.
   PubMed Web of Science ®Google Scholar
• Puls M, Korte KP, Bleckmann A, et al. Long-term outcomes after TAVI in patients with different types of aortic stenosis: the conundrum of low flow, low gradient and low ejection fraction. EuroIntervention J Eur Collab Work Group Interv Cardiol Eur Soc Cardiol. 2017;13:286–293.
   Google Scholar
• Bavishi C, Balasundaram K, Argulian E. Integration of flow-gradient patterns into clinical decision making for patients with suspected severe aortic stenosis and preserved LVEF: a systematic review of evidence and meta-analysis. JACC Cardiovasc Imaging. 2016;9(11):1255–1263.
   PubMed Web of Science ®Google Scholar
• Fischer-Rasokat U, Renker M, Liebetrau C, et al. Outcome of patients with heart failure after transcatheter aortic valve implantation. PloS One. 2019;14(11):e0225473.
   PubMed Web of Science ®Google Scholar
• **Salaun E, Clavel MA, Hahn RT, et al. Outcome of flow-gradient patterns of aortic stenosis after aortic valve replacement: An analysis of the PARTNER 2 trial and registry. Circ Cardiovasc Interv. 2020;13:e008792.
   PubMed Web of Science ®Google Scholar
• Amabile N, Agostini H, Gilard M, et al. Impact of low preprocedural transvalvular gradient on cardiovascular mortality following TAVI: an analysis from the FRANCE 2 registry. EuroIntervention. 2014;10:842–849.
   PubMed Web of Science ®Google Scholar
• Conrotto F, D’Ascenzo F, D’Amico M, et al. Outcomes of patients with low-pressure aortic gradient undergoing transcatheter aortic valve implantation: a Meta-analysis. Catheter Cardiovasc Interv. 2017;89(6):1100–1106.
   PubMed Web of Science ®Google Scholar
• Steiner J, Rodés-Cabau J, Holmes DR, et al. Mechanical intervention for aortic valve stenosis in patients with heart failure and reduced ejection fraction. J Am Coll Cardiol. 2017;70(24):3026–3041.
   PubMed Web of Science ®Google Scholar
• Ribeiro HB, Lerakis S, Gilard M, et al. Transcatheter aortic valve replacement in patients with low-flow, low-gradient aortic stenosis: the TOPAS-TAVI Registry. J Am Coll Cardiol. 2018;71(12):1297–1308.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Gabella T, Nombela-Franco L, Auffret V, et al. Transcatheter aortic valve implantation in patients with paradoxical low-flow, low-gradient aortic stenosis. Am J Cardiol. 2018;122(4):625–632.
   PubMed Web of Science ®Google Scholar
• Cornwell GG, Murdoch WL, Kyle RA, et al. Frequency and distribution of senile cardiovascular amyloid A clinicopathologic correlation. Am J Med. 1983;75(4):618–623.
   PubMed Web of Science ®Google Scholar
• Lane T, Fontana M, Martinez-Naharro A, et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation. 2019;140(1):16–26.
   PubMed Web of Science ®Google Scholar
• González-López E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2585–2594.
   PubMed Web of Science ®Google Scholar
• Dorbala S, Ando Y, Bokhari S, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol. 2019;26:2065–2123.
   PubMed Web of Science ®Google Scholar
• Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007–1016.
   PubMed Web of Science ®Google Scholar
• Castaño A, Narotsky DL, Hamid N, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017;38(38):2879–2887.
   PubMed Web of Science ®Google Scholar
• Nitsche C, Scully PR, Patel KP, et al. Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis. J Am Coll Cardiol. 2021 Jan 19;77(2):128-139;
   PubMed Web of Science ®Google Scholar
• Nitsche C, Aschauer S, Kammerlander AA, et al. Light-chain and transthyretin cardiac amyloidosis in severe aortic stenosis: prevalence, screening possibilities, and outcome. Eur J Heart Fail. 2020;22(10):1852–1862.
   PubMed Web of Science ®Google Scholar
• *Scully PR, Patel KP, Treibel TA, et al. Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation. Eur Heart J. 2020;41(29):2759–2767.
   PubMed Web of Science ®Google Scholar
• Rosenblum H, Masri A, Narotsky DL, et al. Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis. Eur J Heart Fail.2021 Feb;23(2):250-258;
   PubMed Web of Science ®Google Scholar
• Mohty D, Damy T, Cosnay P, et al. Cardiac amyloidosis: updates in diagnosis and management. Arch Cardiovasc Dis. 2013;106(10):528–540.
   PubMed Web of Science ®Google Scholar
• Rubinow A, Skinner M, Cohen AS. Digoxin sensitivity in amyloid cardiomyopathy. Circulation. 1981;63(6):1285–1288.
   PubMed Web of Science ®Google Scholar
• Bouhour JB, Haddak M, Lefevre M. [Risks of beta-blockers and calcium inhibitors in amyloid cardiopathy]. Presse Medicale Paris Fr 1983. 1986;15:981.
   Google Scholar
• Ruberg FL, Grogan M, Hanna M, et al. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73(22):2872–2891.
   PubMed Web of Science ®Google Scholar
• Aimo A, Vergaro G, Castiglione V, et al. Safety and tolerability of neurohormonal antagonism in cardiac amyloidosis. Eur J Intern Med. 2020;80:66–72.
   PubMed Web of Science ®Google Scholar
• Lindman BR, Stewart WJ, Pibarot P, et al. Early regression of severe left ventricular hypertrophy after transcatheter aortic valve replacement is associated with decreased hospitalizations. JACC Cardiovasc Interv. 2014;7(6):662–673.
   PubMed Web of Science ®Google Scholar
• Chin CWL, Everett RJ, Kwiecinski J, et al. Myocardial Fibrosis and Cardiac Decompensation in Aortic Stenosis. JACC Cardiovasc Imaging. 2017;10(11):1320–1333. .
   PubMed Web of Science ®Google Scholar
• Treibel TA, Kozor R, Schofield R, et al. Reverse myocardial remodeling following valve replacement in patients with aortic stenosis. J Am Coll Cardiol. 2018;71(8):860–871.
   PubMed Web of Science ®Google Scholar
• Sugiura A, Weber M, von Depka A, et al. Outcomes of myocardial fibrosis in patients undergoing transcatheter aortic valve replacement. EuroIntervention. 2020;15:1417–1423.
   PubMed Web of Science ®Google Scholar
• Nacif MS, Kawel N, Lee JJ, et al. Interstitial myocardial fibrosis assessed as extracellular volume fraction with low-radiation-dose cardiac CT. Radiology. 2012;264(3):876–883.
   PubMed Web of Science ®Google Scholar
• *Tamarappoo B, Han D, Tyler J, et al. Prognostic Value of Computed Tomography-Derived Extracellular Volume in TAVR Patients With Low-Flow Low-Gradient Aortic Stenosis. JACC Cardiovasc Imaging. 2020;13(12):2591–2601.
   PubMed Web of Science ®Google Scholar
• d’Arcy JL, Coffey S, Loudon MA, et al. Large-scale community echocardiographic screening reveals a major burden of undiagnosed valvular heart disease in older people: the OxVALVE Population Cohort Study†. Eur Heart J. 2016;37(47):3515–3522.
   PubMed Web of Science ®Google Scholar
• Nombela-Franco L, Eltchaninoff H, Zahn R, et al. Clinical impact and evolution of mitral regurgitation following transcatheter aortic valve replacement: a meta-analysis. Heart. 2015;101:1395–1405.
   PubMed Web of Science ®Google Scholar
• Baumgartner H, Hung J, Bermejo J, et al. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. Eur J Echocardiogr. 2009;10(1):1–25.
   PubMed Web of Science ®Google Scholar
• Unger P, Pibarot P, Tribouilloy P, et al. Multiple and mixed valvular heart diseases. Circ Cardiovasc Imaging. 2018;11:e007862.
   PubMed Web of Science ®Google Scholar
• Khawaja MZ, Williams R, Hung J, et al. Impact of preprocedural mitral regurgitation upon mortality after transcatheter aortic valve implantation (TAVI) for severe aortic stenosis. Heart. 2014;100:1799–1803.
   PubMed Web of Science ®Google Scholar
• Mavromatis K, Thourani VH, Stebbins A, et al. Transcatheter aortic valve replacement in patients with aortic stenosis and mitral regurgitation. Ann Thorac Surg. 2017;104(6):1977–1985.
   PubMed Web of Science ®Google Scholar
• Freitas-Ferraz AB, Lerakis S, Barbosa Ribeiro H, et al. Mitral Regurgitation in Low-Flow, Low-Gradient Aortic Stenosis Patients Undergoing TAVR: insights From the TOPAS-TAVI Registry. JACC Cardiovasc Interv. 2020;13(5):567–579.
   PubMed Web of Science ®Google Scholar
• Jerez-Valero M, Urena M, Webb JG, et al. Clinical impact of aortic regurgitation after transcatheter aortic valve replacement: insights into the degree and acuteness of presentation. JACC Cardiovasc Interv. 2014;7(9):1022–1032.
   PubMed Web of Science ®Google Scholar
• Van Belle E, Juthier F, Susen S, et al. Postprocedural aortic regurgitation in balloon-expandable and self-expandable transcatheter aortic valve replacement procedures: analysis of predictors and impact on long-term mortality: insights from the FRANCE2 Registry. Circulation. 2014;129(13):1415–1427.
   PubMed Web of Science ®Google Scholar
• Del Val D, Regueiro A, Rodríguez-Gabella T, et al. Concomitant or staged transcatheter treatment for severe combined aortic and mitral valve disease. Rev Espanola Cardiol Engl Ed. 2018;71(8):676–679.
   PubMed Web of Science ®Google Scholar
• Del Val D, Ferreira-Neto AN, Wintzer-Wehekind J, et al. Early experience with transcatheter mitral valve replacement: a Systematic Review. J Am Heart Assoc. 2019;8(17):e013332.
   PubMed Web of Science ®Google Scholar
• Asmarats L, Puri R, Latib A, et al. Transcatheter Tricuspid Valve Interventions: landscape, Challenges, and Future Directions. J Am Coll Cardiol. 2018;71(25):2935–2956.
   PubMed Web of Science ®Google Scholar
• Patzelt J, Ulrich M, Becker A, et al. Previous TAVR in patients undergoing percutaneous edge-to-edge mitral valve repair (PMVR) affects improvement of MR. PloS One. 2018;13(10):e0205930.
   PubMed Web of Science ®Google Scholar
• Rudolph V, Schirmer J, Franzen O, et al. Bivalvular transcatheter treatment of high-surgical-risk patients with coexisting severe aortic stenosis and significant mitral regurgitation. Int J Cardiol. 2013;167(3):716–720.
   PubMed Web of Science ®Google Scholar
• Rosenkranz S, Gibbs JSR, Wachter R, et al. Left ventricular heart failure and pulmonary hypertension. Eur Heart J. 2016;37(12):942–954.
   PubMed Web of Science ®Google Scholar
• Galiè N, Humbert M, Vachiery J-L, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37:67–119.
   PubMed Web of Science ®Google Scholar
• Asami M, Stortecky S, Praz F, et al. Prognostic value of right ventricular dysfunction on clinical outcomes after transcatheter aortic valve replacement. JACC Cardiovasc Imaging. 2019;12(4):577–587.
   PubMed Web of Science ®Google Scholar
• Lindman BR, Maniar HS, Jaber WA, et al. Effect of tricuspid regurgitation and the right heart on survival after transcatheter aortic valve replacement: insights from the Placement of Aortic Transcatheter Valves II inoperable cohort. Circ Cardiovasc Interv. 2015;8(4).
   Google Scholar
• D’Ascenzo F, Conrotto F, Salizzoni S, et al. Incidence, predictors, and impact on prognosis of systolic pulmonary artery pressure and its improvement after transcatheter aortic valve implantation: a multicenter registry. J Invasive Cardiol. 2015;27:114–119.
   PubMed Web of Science ®Google Scholar
• Ito S, Pislaru SV, Soo WM, et al. Impact of right ventricular size and function on survival following transcatheter aortic valve replacement. Int J Cardiol. 2016;221:269–274.
   PubMed Web of Science ®Google Scholar
• Kempny A, Diller G-P, Kaleschke G, et al. Impact of transcatheter aortic valve implantation or surgical aortic valve replacement on right ventricular function. Heart Br Card Soc. 2012;98:1299–1304.
   PubMed Web of Science ®Google Scholar
• Sinning JM, Hammerstingl C, Chin D, et al. Decrease of pulmonary hypertension impacts on prognosis after transcatheter aortic valve replacement. EuroIntervention. 2014;9:1042–1049.
   PubMed Web of Science ®Google Scholar
• Grevious SN, Fernandes MF, Annor AK, et al. Prognostic assessment of right ventricular systolic dysfunction on post-transcatheter aortic valve replacement short-term outcomes: systematic review and meta-analysis. J Am Heart Assoc. 2020;9(12):e014463.
   PubMed Web of Science ®Google Scholar
• Imad H, Mohammed Selma F, Forfia Paul R, et al. Impaired right ventricular–pulmonary arterial coupling and effect of sildenafil in heart failure with preserved ejection fraction. Circ Heart Fail. 2016;9:e002729.
   PubMed Web of Science ®Google Scholar
• Guazzi M, Bandera F, Pelissero G, et al. Tricuspid annular plane systolic excursion and pulmonary arterial systolic pressure relationship in heart failure: an index of right ventricular contractile function and prognosis. Am J Physiol Heart Circ Physiol. 2013;305(9):H1373–1381.
   PubMed Web of Science ®Google Scholar
• Eleid MF, Padang R, Pislaru SV, et al. Effect of transcatheter aortic valve replacement on right ventricular-pulmonary artery coupling. JACC Cardiovasc Interv. 2019;12(21):2145–2154.
   PubMed Web of Science ®Google Scholar
• Alushi B, Beckhoff F, Leistner D, et al. Pulmonary Hypertension in Patients With Severe Aortic Stenosis: prognostic Impact After Transcatheter Aortic Valve Replacement: pulmonary Hypertension in Patients Undergoing TAVR. JACC Cardiovasc Imaging. 2019;12(4):591–601.
   PubMed Web of Science ®Google Scholar
• Abdelkarim I, Althouse AD, Thoma FW, et al. The Importance of Invasive Hemodynamics for Pulmonary Hypertension Screening in TAVR Patients. J Am Coll Cardiol. 2017;70(4):510–511.
   PubMed Web of Science ®Google Scholar
• Hindricks G, Potpara T, Dagres N, et al. ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021 Feb 1;42(5):541-543.
   Web of Science ®Google Scholar
• Levy F, Garayalde E, Quere JP, et al. Prognostic value of preoperative atrial fibrillation in patients with aortic stenosis and low ejection fraction having aortic valve replacement. Am J Cardiol. 2006;98(6):809–811.
   PubMed Web of Science ®Google Scholar
• Mok M, Urena M, Nombela-Franco L, et al. Clinical and prognostic implications of existing and new-onset atrial fibrillation in patients undergoing transcatheter aortic valve implantation. J Thromb Thrombolysis. 2013;35(4):450–455.
   PubMed Web of Science ®Google Scholar
• Hioki H, Watanabe Y, Kozuma K, et al. Timing of susceptibility to mortality and heart failure in patients with preexisting atrial fibrillation after transcatheter aortic valve implantation. Am J Cardiol. 2017;120(9):1618–1625.
   PubMed Web of Science ®Google Scholar
• Thomas L, Abhayaratna WP. Left atrial reverse remodeling: mechanisms, evaluation, and clinical significance. JACC Cardiovasc Imaging. 2017;10(1):65–77.
   PubMed Web of Science ®Google Scholar
• D’ascenzo F, Verardi R, Visconti M, et al. Independent impact of extent of coronary artery disease and percutaneous revascularisation on 30-day and one-year mortality after TAVI: a meta-analysis of adjusted observational results Eurointervention. 2018;14:e1169–e1177.
   Google Scholar
• Kesavan S, Kinjal B, Krishna K, et al. Impact of coronary artery disease on 30‐Day and 1‐Year mortality in patients undergoing transcatheter aortic valve replacement: a Meta‐Analysis. J Am Heart Assoc. 2017 Oct 11;6(10):e006092.
   Google Scholar
• Neumann F-J, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40:87–165.
   PubMed Web of Science ®Google Scholar
• Faroux L, Guimaraes L, Wintzer-Wehekind J, et al. Coronary artery disease and transcatheter aortic valve replacement: jacc state-of-the-art review. J Am Coll Cardiol. 2019;74(3):362–372.
   PubMed Web of Science ®Google Scholar
• Faroux L, Campelo-Parada F, Munoz-Garcia E, et al. Procedural characteristics and late outcomes of percutaneous coronary intervention in the workup pre-TAVR. JACC Cardiovasc Interv. 2020;13(22):2601–2613.
   PubMed Web of Science ®Google Scholar
• Bahit MC, Kochar A, Granger CB. Post-myocardial infarction heart failure. JACC Heart Fail. 2018;6(3):179–186.
   PubMed Web of Science ®Google Scholar
• Carmona A, Marchandot B, Severac F, et al. Impact of incomplete coronary revascularization on late ischemic and bleeding events after transcatheter aortic valve replacement. J Clin Med. 2020 Jul 16;9(7):2267.
   Web of Science ®Google Scholar
• Aalaei-Andabili SH, Bavry AA. Left ventricular diastolic dysfunction and transcatheter aortic valve replacement outcomes: a review. Cardiol Ther. 2019;8(1):21–28.
   PubMed Web of Science ®Google Scholar
• Asami M, Lanz J, Stortecky S, et al. The impact of left ventricular diastolic dysfunction on clinical outcomes after transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2018;11(6):593–601.
   PubMed Web of Science ®Google Scholar
• Krayenbuehl HP, Hess OM, Monrad ES, et al. Left ventricular myocardial structure in aortic valve disease before, intermediate, and late after aortic valve replacement. Circulation. 1989;79(4):744–755.
   PubMed Web of Science ®Google Scholar
• Okafor I, Raghav V, Midha P, et al. The hemodynamic effects of acute aortic regurgitation into a stiffened left ventricle resulting from chronic aortic stenosis. Am J Physiol Heart Circ Physiol. 2016;310(11):H1801–1807.
   PubMed Web of Science ®Google Scholar
• Auffret V, Puri R, Urena M, et al. Conduction disturbances after transcatheter aortic valve replacement: current status and future perspectives. Circulation. 2017;136(11):1049–1069.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–2200.
   PubMed Web of Science ®Google Scholar
• Exner DV, Birnie DH, Moe G, et al. Canadian cardiovascular society guidelines on the use of cardiac resynchronization therapy: evidence and patient selection. Can J Cardiol. 2013;29(2):182–195.
   PubMed Web of Science ®Google Scholar
• Carabba N, Valenti R, Migliorini A, et al. Impact on Left Ventricular Function and Remodeling and on 1-Year outcome in patients with left bundle branch block after transcatheter aortic valve implantation. Am J Cardiol. 2015;116(1):125–131.
   PubMed Web of Science ®Google Scholar
• Hoffmann R, Herpertz R, Lotfipour S, et al. Impact of a new conduction defect after transcatheter aortic valve implantation on left ventricular function. JACC Cardiovasc Interv. 2012;5(12):1257–1263.
   PubMed Web of Science ®Google Scholar
• *Urena M, Mok M, Serra V, et al. Predictive factors and long-term clinical consequences of persistent left bundle branch block following transcatheter aortic valve implantation with a balloon-expandable valve. J Am Coll Cardiol. 2012;60(18):1743–1752.
   PubMed Web of Science ®Google Scholar
• Zhang X-H, Chen H, Siu C-W, et al. New-onset heart failure after permanent right ventricular apical pacing in patients with acquired high-grade atrioventricular block and normal left ventricular function. J Cardiovasc Electrophysiol. 2008;19(2):136–141.
   PubMed Web of Science ®Google Scholar
• Jørgensen TH, De Backer O, Gerds TA, et al. Mortality and heart failure hospitalization in patients with conduction abnormalities after transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2019;12(1):52–61.
   PubMed Web of Science ®Google Scholar
• López-Aguilera J, Segura Saint-Gerons JM, Sánchez Fernández J, et al. Long-term clinical impact of permanent cardiac pacing after transcatheter aortic valve implantation with the CoreValve prosthesis: a single center experience. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol. 2018;20:993–1000.
   Google Scholar
• *Chamandi C, Barbanti M, Munoz-Garcia A, et al. Long-term outcomes in patients with new permanent pacemaker implantation following transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2018;11(3):301–310.
   PubMed Web of Science ®Google Scholar
• Nazif TM, Dizon JM, Hahn RT, et al. Predictors and clinical outcomes of permanent pacemaker implantation after transcatheter aortic valve replacement: the PARTNER (Placement of AoRtic TraNscathetER Valves) trial and registry. JACC Cardiovasc Interv. 2015;8(1):60–69.
   PubMed Web of Science ®Google Scholar
• Dizon JM, Nazif TM, Hess PL, et al. Chronic pacing and adverse outcomes after transcatheter aortic valve implantation. Heart Br Card Soc. 2015;101:1665–1671.
   PubMed Web of Science ®Google Scholar
• Sakatani T, Sakamoto A, Kawamura K, et al. Clinical outcome after permanent pacemaker implantation in patients with a high percentage of ventricular pacing. Int Heart J. 2015;56(6):622–625.
   PubMed Web of Science ®Google Scholar
• Kron J, Padala SK, Block Post-TAVR: AV. When AV block is high, we go low (in the conduction system). JACC Clin Electrophysiol. 2020;6(6):658–660.
   PubMedGoogle Scholar
• Vijayaraman P, Ó C, Koruth JS, et al. His-purkinje conduction system pacing following transcatheter aortic valve replacement: feasibility and safety. JACC Clin Electrophysiol. 2020;6(6):649–657.
   PubMedGoogle Scholar
• Athappan G, Patvardhan E, Tuzcu EM, et al. Incidence, predictors, and outcomes of aortic regurgitation after transcatheter aortic valve replacement: meta-analysis and systematic review of literature. J Am Coll Cardiol. 2013;61(15):1585–1595.
   PubMed Web of Science ®Google Scholar
• Binder RK, Webb JG, Willson AB, et al. The impact of integration of a multidetector computed tomography annulus area sizing algorithm on outcomes of transcatheter aortic valve replacement: a prospective, multicenter, controlled trial. J Am Coll Cardiol. 2013;62(5):431–438.
   PubMed Web of Science ®Google Scholar
• *Barbanti M, Buccheri S, Rodés-Cabau J, et al. Transcatheter aortic valve replacement with new-generation devices: a systematic review and meta-analysis. Int J Cardiol. 2017;245:83–89.
   PubMed Web of Science ®Google Scholar
• Sinning JM, Vasa-Nicotera M, Chin D, et al. Evaluation and management of paravalvular aortic regurgitation after transcatheter aortic valve replacement. J Am Coll Cardiol. 2013;62(1):11–20.
   PubMed Web of Science ®Google Scholar
• Ribeiro HB, Le Ven F, Larose E, et al. Cardiac magnetic resonance versus transthoracic echocardiography for the assessment and quantification of aortic regurgitation in patients undergoing transcatheter aortic valve implantation. Heart. 2014;100:1924–1932.
   PubMed Web of Science ®Google Scholar
• Pibarot P, Dumesnil JG. Prosthesis-patient mismatch: definition, clinical impact, and prevention. Heart. 2006;92(8):1022–1029.
   PubMed Web of Science ®Google Scholar
• Herrmann HC, Daneshvar SA, Fonarow GC, et al. Prosthesis-patient mismatch in patients undergoing transcatheter aortic valve replacement: from the STS/ACC TVT Registry. J Am Coll Cardiol. 2018;72(22):2701–2711.
   PubMed Web of Science ®Google Scholar
• Zorn GL, Little SH, Tadros P, et al. Prosthesis-patient mismatch in high-risk patients with severe aortic stenosis: a randomized trial of a self-expanding prosthesis. J Thorac Cardiovasc Surg. 2016;151(4):1014–1022. 1023.e1–3.
   PubMed Web of Science ®Google Scholar
• Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence and sequelae of prosthesis-patient mismatch in transcatheter versus surgical valve replacement in high-risk patients with severe aortic stenosis: a PARTNER Trial Cohort-A Analysis. J Am Coll Cardiol. 2014;64(13):1323–1334.
   PubMed Web of Science ®Google Scholar
• Jilaihawi H, Chin D, Spyt T, et al. Prosthesis-patient mismatch after transcatheter aortic valve implantation with the Medtronic-Corevalve bioprosthesis. Eur Heart J. 2010;31(7):857–864.
   PubMed Web of Science ®Google Scholar
• Dvir D, Webb JG, Bleiziffer S, et al. Transcatheter aortic valve implantation in failed bioprosthetic surgical valves. JAMA. 2014;312(2):162–170.
   PubMed Web of Science ®Google Scholar
• Chhatriwalla Adnan K, Allen Keith B, Saxon John T, et al. Bioprosthetic valve fracture improves the hemodynamic results of valve-in-valve transcatheter aortic valve replacement. Circ Cardiovasc Interv. 2017;10:e005216.
   PubMed Web of Science ®Google Scholar
• Shala M, Niclauss L. Early results of the resilia inspiris aortic valve in the old age patients - a retrospective comparison with the carpentier edwards magna ease. J Cardiovasc Thorac Res. 2020;12(3):222–226.
   PubMed Web of Science ®Google Scholar
• Kodali Susheel K, Bapat Vinayak N. Valve in valve for failed surgical bioprostheses. JACC Cardiovasc Interv. 2018;11(2):142–144.
   PubMed Web of Science ®Google Scholar
• Inohara T, Manandhar P, Kosinski AS, et al. Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter aortic valve replacement. JAMA. 2018;320(21):2231–2241.
   PubMed Web of Science ®Google Scholar
• Solomon SD, JJV M, Anand IS, et al. Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381(17):1609–1620.
   PubMed Web of Science ®Google Scholar
• Deswal A, Richardson P, Bozkurt B, et al. Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). J Card Fail. 2011;17(8):634–642.
   PubMed Web of Science ®Google Scholar
• Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation. 2000;102(12):1388–1393.
   PubMed Web of Science ®Google Scholar
• Iwahashi N, Nakatani S, Umemura S, et al. Usefulness of plasma B-type natriuretic peptide in the assessment of disease severity and prediction of outcome after aortic valve replacement in patients with severe aortic stenosis. J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr. 2011;24(9):984–991.
   PubMed Web of Science ®Google Scholar
• Medranda GA, Salhab K, Schwartz R, et al. Prognostic implications of baseline B-type natriuretic peptide in patients undergoing transcatheter aortic valve implantation. Am J Cardiol. 2020;130:94–99.
   PubMed Web of Science ®Google Scholar
• Ribeiro HB, Urena M, Le Ven F, et al. Long-term prognostic value and serial changes of plasma N-terminal prohormone B-type natriuretic peptide in patients undergoing transcatheter aortic valve implantation. Am J Cardiol. 2014;113(5):851–859.
   PubMed Web of Science ®Google Scholar
• Onoda H, Ueno H, Ueno Y, et al. The impact of changes in B-type natriuretic peptide levels on prognosis after transcatheter aortic valve implantation. Cardiovasc Interv Ther. 2020;35(3):283–290.
   PubMed Web of Science ®Google Scholar
• Sobajima M, Imamura T, Onoda H, et al. B-type natriuretic peptide regulation in patients with severe aortic stenosis following transaortic valvular implantation. Int Heart J. 2020;61(4):734–738.
   PubMed Web of Science ®Google Scholar
• Koskinas KC, O’Sullivan CJ, Heg D, et al. Effect of B-type natriuretic peptides on long-term outcomes after transcatheter aortic valve implantation. Am J Cardiol. 2015;116(10):1560–1565.
   PubMed Web of Science ®Google Scholar
• Allen Christopher J, Jubin J, Tiffany P, et al. Baseline NT‐proBNP accurately predicts symptom response to transcatheter aortic valve implantation. J Am Heart Assoc. 2020;9:e017574.
   PubMed Web of Science ®Google Scholar